SEARCH

SEARCH BY CITATION

References

  • 1
    Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995–2004. HEPATOLOGY 2008; 47: 11281135.
  • 2
    Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997–2006. Am J Transplant 2008; 8: 958976.
  • 3
    Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 13721380.
  • 4
    Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. HEPATOLOGY 2005; 41: 790800.
  • 5
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331338.
  • 6
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 15621569.
  • 7
    Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 2001; 323: 11511155.
  • 8
    Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2007; 25: 11531162.
  • 9
    Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004; 11: 148156.
  • 10
    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677684.
  • 11
    Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483491.
  • 12
    Ong JP, Collantes R, Pitts A, Martin L, Sheridan M, Younossi ZM. High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol 2005; 39: 826830.
  • 13
    Swartz MS, Swanson JW, Hannon MJ, Bosworth HS, Osher FC, Essock SM, et al. Regular sources of medical care among persons with severe mental illness at risk of hepatitis C infection. Psychiatr Serv 2003; 54: 854859.
  • 14
    Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat 2001; 8: 377383.
  • 15
    Shehab TM, Orrego M, Chunduri R, Lok AS. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 2003; 98: 639644.
  • 16
    Shiffman ML. A balancing view: we cannot do it alone. Am J Gastroenterol 2007; 102: 18411843.
  • 17
    Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288292.
  • 18
    Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, Gifford A, et al. Predictors of treatment in patients with chronic hepatitis C infection — role of patient versus nonpatient factors. HEPATOLOGY 2007; 46: 17411749.
  • 19
    Rosenberg DM, Cook SF, Lanza LL. Health care, treatment patterns and cost of services for patients infected with chronic hepatitis C virus in a large insured New England population. J Viral Hepat 2000; 7: 361367.
  • 20
    Newman J, Cecchini A. Wolters Kluwer Weekly Prescription Data; February 27, 2009. Oppenheimer Equity Research Industry Update: Healthcare/Specialty Pharmaceuticals 2009; March 9, 2009.
  • 21
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705714.
  • 22
    Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis — United States, 2007. MMWR Surveill Summ 2009; 58: 127.
  • 23
    Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107115.
  • 24
    Arias E. United States life tables, 2004. Natl Vital Stat Rep 2007; 56: 139.
  • 25
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 13351374.
  • 26
    Ezzati TM, Massey JT, Waksberg J, Chu A, Maurer KR. Sample design: Third National Health and Nutrition Examination Survey. Vital Health Stat 2 1992: 135.
  • 27
    Lettmeier B, Muhlberger N, Schwarzer R, Sroczynski G, Wright D, Zeuzem S, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528536.
  • 28
    Hoofnagle JH. A step forward in therapy for hepatitis C. N Engl J Med 2009; 360: 18991901.
  • 29
    Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? Am J Public Health 2003; 93: 635641.
  • 30
    U.S. Preventive Services Task Force. Screening for Hepatitis C: Recommendation Statement. Rockville, MD; 2004.
  • 31
    Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760764.